|
aspirin |
14 |
|
colorectal cancer |
14 |
|
hbv |
14 |
|
liver fibrosis |
14 |
|
epidemiology |
13 |
|
helicobacter pylori |
13 |
|
gastric cancer |
12 |
|
hepatocellular carcinoma |
12 |
|
anti-hbs |
11 |
|
cancer |
11 |
|
chemoprevention |
11 |
|
controlled attenuation parameter |
11 |
|
gastroenterology |
11 |
|
hbsag |
11 |
|
liver stiffness |
11 |
|
nafld |
11 |
|
chronic hepatitis b |
10 |
|
cirrhosis |
10 |
|
colonoscopy |
10 |
|
gastrointestinal bleeding |
10 |
|
hepatitis b |
10 |
|
metformin |
10 |
|
clarithromycin |
9 |
|
fatty liver disease |
9 |
|
hav |
9 |
|
hcv |
9 |
|
hepatitis b core-related antigen |
9 |
|
hepatitis b virus |
9 |
|
hev |
9 |
|
immigration |
9 |
|
nucleoside analogues |
9 |
|
vaccination |
9 |
|
a(h3n2) |
8 |
|
antiviral |
8 |
|
hospitalized |
8 |
|
interval cancer |
8 |
|
naproxen |
8 |
|
oseltamivir |
8 |
|
adenocarcinoma |
7 |
|
alkaline phosphatase |
7 |
|
biliary |
7 |
|
biomarker |
7 |
|
cap |
7 |
|
cholangiogram |
7 |
|
cohort study |
7 |
|
colon cancer |
7 |
|
covid-19 |
7 |
|
elastography |
7 |
|
functional cure |
7 |
|
hepatitis b virus infection |
7 |
|
immortal time bias |
7 |
|
inflammatory bowel disease |
7 |
|
itraq |
7 |
|
ketamine |
7 |
|
m2bpgi |
7 |
|
magnetic resonance cholangiography |
7 |
|
metabolic |
7 |
|
nonsteroidal anti-inflammatory drugs |
7 |
|
obesity |
7 |
|
prevention |
7 |
|
sars-cov-2 |
7 |
|
substance abuse |
7 |
|
type 2 diabetes mellitus |
7 |
|
adult |
6 |
|
anti-hbc |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
aspartate aminotransferase |
6 |
|
colon neoplasms |
6 |
|
covalently closed circular dna |
6 |
|
curative colectomy |
6 |
|
entecavir |
6 |
|
follow up |
6 |
|
gastrointestinal tumours |
6 |
|
gitr |
6 |
|
hcc |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b surface antigen |
6 |
|
hs-hbsag |
6 |
|
intrahepatic hbv dna |
6 |
|
liver cancer |
6 |
|
na therapy |
6 |
|
nucleotide analogue |
6 |
|
pd-1 |
6 |
|
platelet ratio index |
6 |
|
preventive medicine |
6 |
|
primary biliary cholangitis |
6 |
|
primary care |
6 |
|
recurrence |
6 |
|
regulatory t cells |
6 |
|
stomach cancer |
6 |
|
transplantation |
6 |
|
ursodeoxycholic acid |
6 |
|
vcte |
6 |
|
wfa + -m2bp |
6 |
|
angiotensin-converting enzyme inhibitors |
5 |
|
antibiotics |
5 |
|
bacteria |
5 |
|
cancer incidence |
5 |
|
cancer risk |
5 |
|
cohort analysis |
5 |
|
colonic neoplasms |
5 |
|
comorbidity |
5 |
|
endoscopic retrograde cholangiopancreatography |
5 |
|
endoscopic sphicterotomy |
5 |
|
esomeprazole |
5 |
|
fecal-to-oral transmission |
5 |
|
gastrointestinal hemorrhage |
5 |
|
gut microbiota |
5 |
|
hbv // chb |
5 |
|
hepatitis b e antigen |
5 |
|
medical sciences |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
nsaid |
5 |
|
papillotomy |
5 |
|
post‐colonoscopy colorectal cancer |
5 |
|
prisma |
5 |
|
propensity score |
5 |
|
proton pump inhibition |
5 |
|
renin |
5 |
|
s-loss |
5 |
|
sars |
5 |
|
seroclearance |
5 |
|
statins |
5 |
|
telbivudine |
5 |
|
tenofovir |
5 |
|
viraemia |
5 |
|
viral persistence |
5 |
|
adverse outcome |
4 |
|
ageaged |
4 |
|
calcium channel blockers |
4 |
|
cardio-oncology |
4 |
|
carvedilol |
4 |
|
covid-19 vaccine |
4 |
|
cpsh |
4 |
|
drug use |
4 |
|
gastric adenocarcinoma |
4 |
|
h pylori |
4 |
|
heart failure |
4 |
|
helicobacterpylori |
4 |
|
hsct |
4 |
|
intestinal metaplasia |
4 |
|
latency interval |
4 |
|
liver transplant |
4 |
|
malignancy |
4 |
|
nadolol |
4 |
|
non-alcoholic fatty liver disease |
4 |
|
nsbb |
4 |
|
peptic ulcer |
4 |
|
propranolol |
4 |
|
proton pump inhibitors |
4 |
|
rituximab |
4 |
|
statin |
4 |
|
stomach |
4 |
|
thiopurines |
4 |
|
time trend |
4 |
|
varices |
4 |
|
age |
3 |
|
artificial ventilation |
3 |
|
atrial fibrillation |
3 |
|
cerebrovascular accident |
3 |
|
coronavac |
3 |
|
diagnosis |
3 |
|
direct thrombin inhibitor |
3 |
|
factor xa inhibitor |
3 |
|
gastric acid |
3 |
|
h. pylori |
3 |
|
healthcare dataset |
3 |
|
lymph-node metastasis |
3 |
|
magnifying endoscopy |
3 |
|
medical therapy |
3 |
|
meta-analysis |
3 |
|
rectal cancer |
3 |
|
remdesivir |
3 |
|
systematic review |
3 |
|
vaccine |
3 |
|
vaccine immunogenicity |
3 |
|
adverse outcomes |
2 |
|
antibiotic |
2 |
|
antigen |
2 |
|
apixaban |
2 |
|
aryl hydrocarbon receptor |
2 |
|
asia pacific |
2 |
|
asian |
2 |
|
biliary tract - diseases - china - hong kong |
2 |
|
chemopreventive agents |
2 |
|
cohort |
2 |
|
dabigatran |
2 |
|
diabetes mellitus |
2 |
|
edoxaban |
2 |
|
endoscopy |
2 |
|
enterochromaffin-like cells |
2 |
|
etv |
2 |
|
fibrosis |
2 |
|
follow-up |
2 |
|
gastric neoplasia |
2 |
|
gastrin |
2 |
|
ggt |
2 |
|
hepatitis b surface antigens |
2 |
|
levofloxacin |
2 |
|
liver |
2 |
|
mortality |
2 |
|
msrc |
2 |
|
na |
2 |
|
natural history |
2 |
|
novel anticoagulants |
2 |
|
nucleoside analogue |
2 |
|
ppi |
2 |
|
ppis |
2 |
|
prognosis |
2 |
|
qnr family |
2 |
|
real-b |
2 |
|
rivaroxaban |
2 |
|
tdf |
2 |
|
treatment |
2 |
|
triple therapy |
2 |
|
viral hepatitis |
2 |
|
viral suppression |
2 |
|
warfarin |
2 |
|
13c-urea breath test |
1 |
|
bismuth |
1 |
|
next generation sequencing |
1 |
|
ngs |
1 |
|
postcolonoscopy colorectal cancer |
1 |
|
proton pump inhibitor-based regimen |
1 |
|
stool based-pcr |
1 |
|
vonoprazan |
1 |
